Australia Retinal Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Australia · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$168.9 MnPlaceholder estimate
Estimate 2025$181.5 Mn1.1% of the global market
Projected 2034$348.1 Mn 91.7%Adds $166.5 Mn over 9 forecast years
CAGR 2025–20347.5%Faster than 26% of 180 Pharmaceuticals markets here
Key segments of the retinal Disease Drugs market include drug (Aflibercept, Faricimab and Ranibizumab) and indication (Wet AMD, Diabetic Macular Edema and Retinal Vein Occlusion).
Australia Retinal Disease Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Australia Retinal Disease Drugs Market Dynamics
Market Growth Drivers
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Opportunity
Longer-acting treatments, home-based care and screening in emerging markets give the retinal Disease Drugs market room to grow.
Market Restraints
High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the retinal Disease Drugs market.
Competitive Landscape for Retinal Disease Drugs Market in Australia
The retinal Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Retinal Disease Drugs Market in Australia
Retinal Disease Drugs in Australia: rules, payment and research
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2] ClinicalTrials.gov lists 33 studies on Retinal Disease Drugs that are recruiting, active or about to start in Australia.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for retinal Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Regeneron Pharmaceuticals
7.2 Roche
7.3 Bayer AG
7.4 Novartis
7.5 Samsung Bioepis
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The retinal Disease Drugs market can be segmented based on various criteria, including drug, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Retinal Disease Drugs right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Retinal Disease Drugs in context
Australia compared
Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
How big is the Retinal Disease Drugs market in Australia?
Placeholder estimate: about $181.5 Mn in 2025, rising to about $348.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Retinal Disease Drugs market in Australia growing?
Placeholder estimate: about 7.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Retinal Disease Drugs market report cover?
The report splits the market by drug (Aflibercept, Faricimab, Ranibizumab, Biosimilars), indication (Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Retinal Disease Drugs market?
Key players include Regeneron Pharmaceuticals, Roche, Bayer AG, Novartis AG and Samsung Bioepis.
What is driving the Retinal Disease Drugs market?
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Who regulates Retinal Disease Drugs in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Retinal Disease Drugs are running in Australia?
33 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Retinal Disease Drugs?
PubMed lists 1,099 papers on Retinal Disease Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.